Daiichi Sankyo sues Matrix Lab

BV Mahalakshmi
Posted: Thursday, Jun 05, 2008 at 0029 hrs IST
Updated: Thursday, Jun 05, 2008 at 0029 hrs IST

Font Size

Feedback

Discuss

Pfizer’s Handa is new MD of Wyeth India Lower forex losses put Ranbaxy back in the black Pfizer profit up 26% on job cuts Pfizer forms policies to raise standards

Hyderabad, June 4: Hyderabad-based Matrix Laboratories Ltd has been sued by the Tokyo-based Daiichi Sankyo in a patent infringement case. This was confirmed by the Nasdaq-listed Mylan Inc, which has a majority stake in Matrix. The company has been sued by Daiichi Sankyo in connection with Amlodipine Besylate/Olmesartan Medoxomil tablets in the capacities of 5 mg/20 mg, 10 mg/20 mg, 5 mg/40 mg, and 10 mg/40 mg, for its generic version of Daiichi Sankyo's Azor tablets. These tablets are anti-hypertensive in nature and used in the treatment of angina.

Daiichi Sankyo filed a lawsuit on Tuesday in the US district court for the district of New Jersey, alleging infringement of the sole patent relating to Azor, which is listed in the "Orange Book" as US patent No 5,616,599. When contacted, the company officials were not available for comments. Mylan believes that Matrix is the first company to file a substantially complete Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for the product. Matrix filed an ANDA with the US Food and Drug Administration in early 2008.

According to analysts, if Daichii Sankyo wins because of its first-to-file case, it will have a shared 180-exclusivity for marketing this product. As per estimates, Amlodipine tablets have a market size of around $2 billion. The product is currently the largest molecule, which has gone off-patent in Japan and represents the biggest generic opportunity so far in the Japanese generic market.

Post Comments

Comments: (Limit 3,000 characters)

Name		Message
Email ID
Subject

TERMS OF USE:
The views, opinions and comments posted are your, and are not endorsed by this website. You shall be solely responsible for the comment posted here. The website reserves the right to delete, reject, or otherwise remove any views, opinions and comments posted or part thereof. You shall ensure that the comment is not inflammatory, abusive, derogatory, defamatory &/or obscene, or contain pornographic matter and/or does not constitute hate mail, or violate privacy of any person (s) or breach confidentiality or otherwise is illegal, immoral or contrary to public policy. Nor should it contain anything infringing copyright &/or intellectual property rights of any person(s).

I agree to the terms of use.